Biomaterials, Biodegradables and Biomimetics Research Group

Comunication - Oral

Galloyl-terminated dendrimers modulate Aβ42 fibrillization and reduces cellular toxicity


Alzheimer's disease (AD) is characterized by the occurrence of extracellular senile plaques of aggregated amyloid-beta peptide (Ab42). These plaques are generated by the self-assembling of Ab42 monomers into supramolecular nanofibrillar structures stabilized by the peptide’s β-sheets. While the senile plaques are a hallmark of AD, the presence of intracellular soluble Ab42 oligomers (precursors of the senile plaques) are reported to be the main cause of its toxicity [1]

We have previously demonstrated that the use of natural polyphenols can rescue cell viability affected by the Ab42 fibrillization. In fact, the use of EGCG as a modulator of Ab42 self-assembly has been studied, and its ability to block the assembly process has been reported [2]. The activity of EGCG is reported to occur through the interference of the Pi-Pi stacking within the Ab42 supramolecular arrangement [3]. In general, most of the natural polyphenols reported to modulate Ab42 self-assembly present galloyl-type moieties. Based on this observation, we designed dendrimers displaying this type of moieties on their surface and tested them for their ability to modulate Ab42 fibrillization.

We synthesised a G0-GA core dendrimer with two gallates, and a G1-GA one with six gallate groups. We used CD, DLS and fluorescence spectroscopy to evaluate their ability to inhibit Ab42 fibrillization. Our results show that G1-GA is able to decrease the β-sheet content of the Ab42 supramolecular assemblies, while reducing the size of the fibrils. We also confirmed that G1-GA has the capacity of maintain SH-SY5Y cell viability, reducing the oligomeric Aβ42 assemblies in the cytoplasm of the cells. Our results demonstrate that G1-GA dendrimer represents a promising custom-made nanotherapeutical tool able to modulate the toxicity of Ab42 assemblies in the AD context.



[1] Eisele, Y.S., et al.,Nat Rev Drug Discov, 2015. 14(11): p. 759-780.

[2] Meisl, G., et al.,Nat. Protocols, 2016. 11(2): p. 252-272.

[3] Attar, A., F. Rahimi, and G. Bitan, Trans Neuro, 2013. 4(4): p. 385-409.


13th EYCN Delegates Assembly
Alzheimer's disease, natural polyphenols
Open Access
Peer Reviewed
Year of Publication
Date Published
Search Google ScholarGenerate BibTexDownload RTF
This website uses cookies. By using this website you consent to our use of these cookies. For more information visit our Policy Page.